Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,498JPY
20 Jan 2017
Change (% chg)

¥33 (+1.34%)
Prev Close
¥2,465
Open
¥2,479
Day's High
¥2,506
Day's Low
¥2,461
Volume
2,387,700
Avg. Vol
2,587,650
52-wk High
¥2,750
52-wk Low
¥2,078

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.83
Market Cap(Mil.): ¥1,771,110.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.60

Financials

  4568.T Industry Sector
P/E (TTM): 28.17 29.51 30.38
EPS (TTM): 88.69 -- --
ROI: 3.71 15.44 14.86
ROE: 4.99 16.62 16.28

BRIEF-Daiichi Sankyo initiates phase 1/2 study of novel antibody drug conjugate in patients unresectable breast cancer

* Daiichi sankyo initiates phase 1/2 study of novel antibody drug conjugate u3-1402 in patients with her3-positive metastatic or unresectable breast cancer Source text for Eikon: Further company coverage:

18 Jan 2017

BRIEF-Kite Pharma establishes strategic partnership with Daiichi Sankyo

* Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan

09 Jan 2017

Kite Pharma partners with Japan's Daiichi for cancer therapy

Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

09 Jan 2017

Kite Pharma partners with Japan's Daiichi for cancer therapy

Jan 9 Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

09 Jan 2017

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany

01 Nov 2016

BRIEF-Pieris Pharmaceuticals to receive GLP Tox payment in Daiichi Sankyo collaboration

* Pieris Pharmaceuticals to receive GLP tox milestone payment in Daiichi Sankyo collaboration

26 Oct 2016

BRIEF-Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond

* Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology

25 Oct 2016

BRIEF-Daiichi Sankyo completes 20.2 mln shares' buy-back for 50 bln yen

* Says it completes around 20.2 million shares' buy-back for approximately 50 billion yen as of Oct. 24

25 Oct 2016

BRIEF-Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration

* Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer

12 Oct 2016

BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients

* Daiichi Sankyo Co Ltd - first patient has been enrolled in global phase 3 quantum-first study evaluating oral FLT3-ITD inhibitor quizartinib

11 Oct 2016

Earnings vs. Estimates